Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
CN¥18.49 - CN¥27.26
Next Earnings Date
May 20 2025 (Estimate)
Next Earnings Date
May 20 2025 (Est.)
Latest price
Market Cap | CN¥12.61B |
EV | CN¥11.68B |
Shares Outstanding | 563.16M |
Beta | 0.29 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | CN¥23.20 |
P/E 2024E | 18.40x |
P/Revenue 2024E | 3.47x |
Revenue | 12.40% |
EPS | 20.50% |
Operating Cash Flow | 21.80% |
Free Cash Flow | 33.60% |
Revenue | 9.00% |
EPS | 15.10% |
Operating Cash Flow | 3.10% |
Free Cash Flow | 6.80% |
Gross Margin 2024E | 73.55% |
Net Profit Margin 2024E | 18.89% |
ROE 2024E | 23.34% |
ROCE 2023 | 21.27% |
DPS 2024E | CN¥0.95 |
Payout Ratio 2024E | 77.87% |
Div. Yield 2024E | 4.23% |
DPS Last 3Y CAGR | 26.00% |
Price
%
1M
3M
6M
1Y
3Y
5Y
Henan Lingrui Pharmaceutical Co., Ltd.
600285
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Xiong, Wei
Employees
2,530
Website
www.lingrui.comIPO Date
2000-10-18
Headquarters
No.666 Jiangjun Road, Xin County, Xinyang, Henan Province, 465550, China
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved